Scholarly Index
Tamer Coşkun
Eli Lilly (United States); 7,748 total citations; 135 total publications; best world rank #66
Eli Lilly (United States)
7,748Total citations
135Total publications
36H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Fibroblast Growth Factor Research | Lifetime | 773 | US 317 | 91.43 |
| Kruppel-like factors research | Lifetime | 647 | US 241 | 89.97 |
| Diabetes Treatment and Management | 2021-2025 | 267 | US 96 | 97.05 |
| Pharmacology and Obesity Treatment | 2021-2025 | 66 | US 31 | 93.97 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 272 | US 73 | 91.89 |
| Adipose Tissue and Metabolism | 2021-2025 | 948 | US 255 | 87.09 |
| Neuropeptides and Animal Physiology | 2021-2025 | 419 | US 145 | 80.90 |
| Regulation of Appetite and Obesity | 2021-2025 | 777 | US 245 | 68.68 |